血管生成素样蛋白8在心血管疾病发病中作用的研究进展

doi:10.16352/j.issn.1001-6325.2024.04.0544

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (4): 544-547.doi: 10.16352/j.issn.1001-6325.2024.04.0544

血管生成素样蛋白8在心血管疾病发病中作用的研究进展

韩丽杰, 胡朝伟, 于华惠, 秦彦文^*

首都医科大学附属北京安贞医院心血管重塑相关疾病教育部重点实验室,北京 100029

收稿日期:2023-08-10 修回日期:2024-01-18 出版日期:2024-04-05 发布日期:2024-03-25
通讯作者: ^*qinyanwen@vip.126.com
基金资助:
国家自然科学基金(81970224);国家重点研发计划(2021YFC2500600;2021YFC2500603)

Research progress on the roles of angiopoietin-like protein 8 in the pathogenesis of cardiovascular diseases

HAN Lijie, HU Chaowei, YU Huahui, QIN Yanwen^*

The Key Laboratory of Cardiovascular Remodeling-related Diseases, Ministry of Education, Beijing Anzhen Hospital,Capital Medical University, Beijing 100029, China

Received:2023-08-10 Revised:2024-01-18 Online:2024-04-05 Published:2024-03-25
Contact: ^*qinyanwen@vip.126.com

摘要/Abstract

摘要： 血管生成素样蛋白8(ANGPTL8)是由肝脏和脂肪组织合成、分泌的一种糖蛋白,能够促进血管重塑、调节炎性反应,并通过这些机制参与冠心病、高血压、主动脉瘤、病理性心肌肥厚等多种心血管疾病的发生与发展,有望成为心血管疾病新的预防和治疗靶点。

关键词: 血管生成素样蛋白8, 冠心病, 高血压, 主动脉瘤, 病理性心肌肥厚

Abstract: Angiopoietin-like protein 8(ANGPTL8) secreted by liver and adipose tissue, is a glycoprotein exerting paramount effects on facilitation of vascular remodeling and regulation of inflammatory response; ANGPTL8 is involved in the initiation and progression of cardiovascular diseases including coronary artery disease, hypertension, aortic aneurysm and pathological cardiac hypertrophy, and holds promise for being a new target for the prevention and treatment of cardiovascular diseases.

Key words: angiopoietin-like protein 8, coronary artery disease, hypertension, aortic aneurysm, pathological cardiac hypertrophy

中图分类号:

R363.1

韩丽杰, 胡朝伟, 于华惠, 秦彦文. 血管生成素样蛋白8在心血管疾病发病中作用的研究进展[J]. 基础医学与临床, 2024, 44(4): 544-547.

HAN Lijie, HU Chaowei, YU Huahui, QIN Yanwen. Research progress on the roles of angiopoietin-like protein 8 in the pathogenesis of cardiovascular diseases[J]. Basic & Clinical Medicine, 2024, 44(4): 544-547.

参考文献 21

[1]	Wang H, Zhang H, Zou Z. Changing profiles of cardiovascular disease and risk factors in China: a secondary analysis for the Global Burden of Disease Study 2019[J]. Chin Med J(Engl), 2023, 136:2431-2441.
[2]	Xu F, Wang N, Li G, et al. Angptl8/betatrophin improves glucose tolerance in older mice and metabolomic analysis reveals its role in insulin resistance in HepG2 cells[J]. Diabetes Metab Syndr Obes, 2021, 14:4209-4221.
[3]	Jiao X, Yu H, Du Z, et al. Vascular smooth muscle cells specific deletion of angiopoietin-like protein 8 prevents angiotensin II-promoted hypertension and cardiovascular hypertrophy[J]. Cardiovasc Res, 2023, 119:1856-1868.
[4]	Zhang Z, Yuan Y, Hu L, et al. ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways[J]. J Adv Res, 2023, 47:41-56.
[5]	Thorin E, Labbé P, Lambert M, et al. Angiopoietin-like proteins: cardiovascular biology and therapeutic targeting for the prevention of cardiovascular diseases[J]. Can J Cardiol, 2023, 39:1736-1756.
[6]	Abu-Farha M, Ghosh A, Al-Khairi I, et al. The multi-faces of Angptl8 in health and disease: novel functions beyond lipoprotein lipase modulation[J]. Prog Lipid Res, 2020, 80:101067. doi:10.1016/j.plipres.2020.101067.
[7]	Navaeian M, Asadian S, Ahmadpour Yazdi H, et al. ANGPTL8 roles in proliferation, metabolic diseases, hypothyroidism, polycystic ovary syndrome, and signaling pathways[J]. Mol Biol Rep, 2021, 48:3719-3731.
[8]	Yang Y, Yu H, Jiao X, et al. Angiopoietin-like proteins 8 knockout reduces intermittent hypoxia-induced vascular remodeling in a murine model of obstructive sleep apnea[J]. Biochem Pharmacol, 2021, 186:114502. doi:10.1016/j.bcp.2021.114502.
[9]	Li D, Huang L, Kan R, et al. LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis[J]. Nat Commun, 2023, 14:4436. doi:10.1038/s41467-023-40183-3.
[10]	武悦,马宾,刘进军,等. 血管生成素样蛋白8与冠心病患病及严重程度的相关性[J]. 牡丹江医学院学报, 2020, 41:66-70.
[11]	Fan W, Si Y, Xing E, et al. Human epicardial adipose tissue inflammation correlates with coronary artery disease[J]. Cytokine, 2023, 162:156119. doi:10.1016/j.cyto.2022.156119.
[12]	Damrauer SM, Helkkula P, Kiiskinen T, et al. ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease[J]. PLoS Genet, 2021, 17:e1009501. doi:10.1371/journal.pgen.1009501.
[13]	Morinaga J, Kashiwabara K, Torigoe D, et al. Plasma Angptl8 levels and risk for secondary cardiovascular events in Japanese patients with stable coronary artery disease receiving statin therapy[J]. Arterioscler Thromb Vasc Biol, 2023, 43:1549-1559.
[14]	Jiao X, Yang Y, Li L, et al. Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE-/-mice[J]. Atherosclerosis, 2020, 307:63-71.
[15]	Zou F, Li Y, Zhang S, et al. DP1(prostaglandin D2 receptor 1) activation protects against vascular remodeling and vascular smooth muscle cell transition to myofibro-blasts in angiotensin II-induced hypertension in mice[J]. Hypertension, 2022, 79:1203-1215.
[16]	Xu F, Shen L, Yang Y, et al. Association between plasma levels of ANGPTL3, 4, 8 and the most common additional cardiovascular risk factors in patients with hypertension[J]. Diabetes Metab Syndr Obes, 2023, 16:1647-1655.
[17]	Yang Y, Jiao X, Li L, et al. Increased circulating angiopoietin-like protein 8 levels are associated with thoracic aortic dissection and higher inflammatory conditions[J]. Cardiovasc Drugs Ther, 2020, 34:65-77.
[18]	Yang Y, Jiao X, Yu H, et al. Angiopoietin-like protein 8 deficiency attenuates thoracic aortic aneurysm/dissection development in beta-aminopropionitrile monofumarate-induced model mice[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869:166619. doi:10.1016/j.bbadis.2022.166619.
[19]	Yu H, Jiao X, Yang Y, et al. ANGPTL8 deletion attenuates abdominal aortic aneurysm formation in ApoE-/- mice[J]. Clin Sci(Lond), 2023, 137:979-993.
[20]	Hu L, Wei J, Zhang Y, et al. ANGPTL8 is a negative regulator in pathological cardiac hypertrophy[J]. Cell Death Dis, 2022, 13:621. doi:10.1038/s41419-022-05029-8.
[21]	Wang D, Feng D, Wang Y, et al. Angiopoietin-like protein 8/leptin crosstalk influences cardiac mass in youths with cardiometabolic risk: The BCAMS study[J]. Front Endocrinol(Lausanne), 2021, 12:788549. doi:10.3389/fendo.2021.788549.

血管生成素样蛋白8在心血管疾病发病中作用的研究进展

Research progress on the roles of angiopoietin-like protein 8 in the pathogenesis of cardiovascular diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	宋星明, 哈力沙·艾日肯江, 迪丽胡玛尔·阿布来提, 高颖. 内皮脂肪酶作为冠心病治疗靶点的研究进展[J]. 基础医学与临床, 2023, 43(9): 1443-1447.
[2]	蒋晨晨, 崔泽, 潘利, 孙纪新, 何慧婧, 胡耀达, 单广良. 河北省汉族和满族成人高血压家族史与超重/肥胖对高血压发病的交互作用[J]. 基础医学与临床, 2023, 43(7): 1053-1059.
[3]	王春源, 边立立, 李肖肖. 北京月坛社区老年高血压患者抑郁情绪调查及危险因素分析[J]. 基础医学与临床, 2023, 43(5): 798-803.
[4]	王琴, 张晓艳, 刘雪婷, 李炳蔚, 李宏伟, 杨义力, 韩建群. 全杜仲胶囊对自发性高血压大鼠肠壁微血流灌注的影响[J]. 基础医学与临床, 2023, 43(3): 386-392.
[5]	王振花, 李潮生. 饮食作用的肠道菌群-免疫轴与高血压相关性的研究进展[J]. 基础医学与临床, 2022, 42(6): 983-987.
[6]	孙秋菊, 焦晓璐, 于华惠, 李凡, 吕倩雯, 王钰, 秦彦文. 血管生成素样蛋白8促进大鼠主动脉血管平滑肌细胞表型转化[J]. 基础医学与临床, 2022, 42(5): 745-751.
[7]	杜瑾, 申郁冰, 杨翠红, 陈雅丽, 姜晶梅. 新疆阿勒泰市哈萨克族不同职业人群高血压相关因素分析[J]. 基础医学与临床, 2022, 42(4): 577-582.
[8]	计慧芳, 付阳, 董一飞. 时钟基因PER调控血压的研究进展[J]. 基础医学与临床, 2022, 42(2): 311-315.
[9]	石阳, 毕晓磊, 邵一兵. 冬泳在急性心肌梗死发病学中作用的研究进展[J]. 基础医学与临床, 2022, 42(12): 1921-1924.
[10]	游慧, 康海军, 陈方, 李恒. 高血压视网膜病变患者外周血单个核细胞Notch1水平及其与血管内皮功能的相关性[J]. 基础医学与临床, 2022, 42(10): 1528-1532.
[11]	易达松, 袁善斌, 曾俊义, 赵健清, 丁露, 文通, 聂俊刚. 自发性高血压大鼠年龄相关性左心室肥厚的动态变化[J]. 基础医学与临床, 2022, 42(10): 1481-1486.
[12]	高川, 周俞余, 高莹, 何仲. 稳定性冠心病诊疗中患者参与临床决策质量及其影响因素[J]. 基础医学与临床, 2022, 42(10): 1572-1576.
[13]	王书畅, 朱惠娟, 潘慧. 肢端肥大症与高血压[J]. 基础医学与临床, 2021, 41(9): 1366-1370.
[14]	于华惠, 焦晓璐, 杨云云, 李凡, 孙秋菊, 玉钰, 吕倩雯, 秦彦文. 血管生成素样蛋白3基因敲低减轻胸主动脉瘤的发生和发展[J]. 基础医学与临床, 2021, 41(5): 680-687.
[15]	李肖肖, 边立立, 董玉明, 李娟, 刘丹丹. 月坛社区高血压患者用药及血压控制情况调查[J]. 基础医学与临床, 2021, 41(1): 93-96.